Press Release: Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update

Dow Jones05-15

Email: davidluci@acurxpharma.com 

 
                     ACURX PHARMACEUTICALS, INC. 
 
                   CONDENSED INTERIM BALANCE SHEETS 
 
 
                                            March 31,    December 31, 
                                              2024           2023 
                                          -------------  ------------- 
                                           (unaudited)     (Note 2) 
ASSETS 
--------------------------------------- 
 
CURRENT ASSETS 
 Cash                                     $   8,920,926  $   7,474,188 
 Other Receivable                                    --        129,159 
 Prepaid Expenses                               187,908        105,776 
                                           ------------   ------------ 
   TOTAL ASSETS                           $   9,108,834  $   7,709,123 
                                           ============   ============ 
 
LIABILITIES AND SHAREHOLDERS' EQUITY 
--------------------------------------- 
 
CURRENT LIABILITIES 
 Accounts Payable and Accrued Expenses    $   3,110,242  $   3,042,438 
                                           ------------   ------------ 
   TOTAL CURRENT LIABILITIES                  3,110,242      3,042,438 
                                           ------------   ------------ 
 
   TOTAL LIABILITIES                          3,110,242      3,042,438 
                                           ------------   ------------ 
 
COMMITMENTS AND CONTINGENCIES 
 
SHAREHOLDERS' EQUITY 
Common Stock; $.001 par value, 
 200,000,000 shares authorized, 
 15,757,102 and 14,468,229 shares issued 
 and outstanding at March 31, 2024 and 
 December 31, 2023, respectively                 15,757         14,468 
Additional Paid-In Capital                   63,579,577     57,871,070 
Accumulated Deficit                        (57,596,742)   (53,218,853) 
                                           ------------   ------------ 
 
   TOTAL SHAREHOLDERS' EQUITY                 5,998,592      4,666,685 
                                           ------------   ------------ 
 
TOTAL LIABILITIES AND SHAREHOLDERS' 
 EQUITY                                   $   9,108,834  $   7,709,123 
                                           ============   ============ 
 
 
                    ACURX PHARMACEUTICALS, INC. 
 
             CONDENSED INTERIM STATEMENTS OF OPERATIONS 
 
 
                                            Three Months Ended 
                                                March 31, 
                                        -------------------------- 
                                            2024          2023 
                                        ------------  ------------ 
                                        (unaudited)   (unaudited) 
OPERATING EXPENSES 
Research and Development                $  1,555,011  $  1,015,583 
General and Administrative                 2,822,878     1,887,374 
                                         -----------   ----------- 
 
TOTAL OPERATING EXPENSES                   4,377,889     2,902,957 
                                         -----------   ----------- 
 
NET LOSS                                $(4,377,889)  $(2,902,957) 
                                         ===========   =========== 
 
LOSS PER SHARE 
Basic and diluted net loss per common 
 share                                  $     (0.28)  $     (0.25) 
                                         ===========   =========== 
 
Weighted average common shares 
 outstanding, basic and diluted           15,472,507    11,639,395 
                                         ===========   ===========

View original content:https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-inc-reports-first-quarter-2024-results-and-provides-business-update-302145358.html

SOURCE Acurx Pharmaceuticals, Inc.

(END) Dow Jones Newswires

May 15, 2024 07:00 ET (11:00 GMT)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment